Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the future
Martin Rao, Giuseppe Ippolito, Sayoki Mfinanga, et al.
International Journal of Infectious Diseases (2019) Vol. 80, pp. S62-S67
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Management of drug-resistant tuberculosis
Christoph Lange, Keertan Dheda, Dumitru Chesov, et al.
The Lancet (2019) Vol. 394, Iss. 10202, pp. 953-966
Closed Access | Times Cited: 249
Therapeutic host-directed strategies to improve outcome in tuberculosis
Carly Young, Gerhard Walzl, Nelita du Plessis
Mucosal Immunology (2019) Vol. 13, Iss. 2, pp. 190-204
Open Access | Times Cited: 162
Urogenital tuberculosis — epidemiology, pathogenesis and clinical features
Asıf Muneer, Bruce Macrae, Sriram Krishnamoorthy, et al.
Nature Reviews Urology (2019) Vol. 16, Iss. 10, pp. 573-598
Open Access | Times Cited: 157
Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models
Saloni Saxena, Herman P. Spaink, Gabriel Forn‐Cuní
Biology (2021) Vol. 10, Iss. 2, pp. 96-96
Open Access | Times Cited: 108
Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
Amalia Anastasopoulou, Dimitrios C. Ziogas, Michael Samarkos, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 103
Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection
Kai Ling Chin, Luis Anibarro, María E. Sarmiento, et al.
Tropical Medicine and Infectious Disease (2023) Vol. 8, Iss. 2, pp. 89-89
Open Access | Times Cited: 16
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance
Summaya Perveen, Diksha Kumari, Kuljit Singh, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114066-114066
Closed Access | Times Cited: 39
Relevance of the Warburg Effect in Tuberculosis for Host-Directed Therapy
Bridgette M. Cumming, Hayden T. Pacl, Adrie J. C. Steyn
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 35
New advances in the treatments of drug-resistant tuberculosis
M. Mahmoud, Yurong Tan
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 8, pp. 863-870
Closed Access | Times Cited: 11
Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis
Sapna Saini, Anjali Gangwar, Rashmi Sharma
Microbiological Research (2023) Vol. 275, pp. 127466-127466
Open Access | Times Cited: 11
Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment
Omobolanle A. Omoteso, Adewale Oluwaseun Fadaka, Roderick B. Walker, et al.
Microorganisms (2025) Vol. 13, Iss. 4, pp. 722-722
Open Access
Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies
Martin Rao, Ernest Dodoo, Alimuddin Zumla, et al.
Frontiers in Microbiology (2019) Vol. 10
Open Access | Times Cited: 24
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape
Patrick Phillips, Carole D. Mitnick, James D. Neaton, et al.
PLoS Medicine (2019) Vol. 16, Iss. 3, pp. e1002767-e1002767
Open Access | Times Cited: 23
Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities
Kai Ling Chin, Luis Anibarro, Zi Yuan Chang, et al.
Current Research in Microbial Sciences (2024) Vol. 7, pp. 100295-100295
Open Access | Times Cited: 2
Sirtuin inhibitors reduce intracellular growth of M. tuberculosis in human macrophages via modulation of host cell immunity
Sadaf Kalsum, Mira Akber, Marco Giulio Loreti, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles
Leon J. Khoza, Pradeep Kumar, Admire Dube, et al.
International Journal of Pharmaceutics (2022) Vol. 622, pp. 121893-121893
Open Access | Times Cited: 12
Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management
Nguyen Quang Thu, Nguyen Tran Nam Tien, Nguyen Thi Hai Yen, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 14, Iss. 1, pp. 16-38
Open Access | Times Cited: 6
Host-directed therapies and holistic care for tuberculosis
Alimuddin Zumla, Giuseppe Ippolito, Francine Ntoumi, et al.
The Lancet Respiratory Medicine (2020) Vol. 8, Iss. 4, pp. 337-340
Open Access | Times Cited: 15
ArgD of Mycobacterium tuberculosis is a functional N-acetylornithine aminotransferase with moonlighting function as an effective immune modulator
Iqra Bashir Nehvi, Neha Quadir, Mohd Khubaib, et al.
International Journal of Medical Microbiology (2021) Vol. 312, Iss. 1, pp. 151544-151544
Open Access | Times Cited: 14
Antimicrobial and Antioxidant Potential of Vernonia Cinerea Extract Coated AuNPs
L. B. Singh, Reena Antil, Pushpa Dahiya
Indian Journal of Microbiology (2021) Vol. 61, Iss. 4, pp. 506-518
Open Access | Times Cited: 12
Novel Organic Salts Based on Mefloquine: Synthesis, Solubility, Permeability, and In Vitro Activity against Mycobacterium tuberculosis
Dário Silva, Márcio Vinicius Costa Lopes, Željko Petrovski, et al.
Molecules (2022) Vol. 27, Iss. 16, pp. 5167-5167
Open Access | Times Cited: 7
Revolutionary new treatment regimens for multidrug-resistant tuberculosis
Timothy D. McHugh, Isobella Honeyborne, Marc Lipman, et al.
The Lancet Infectious Diseases (2019) Vol. 19, Iss. 3, pp. 233-234
Open Access | Times Cited: 7
The treatment of tuberculosis under current conditions
М. В. Синицын, M.V. Kalinina, Evgeny Belilovskiy, et al.
Terapevticheskii arkhiv (2020) Vol. 92, Iss. 8, pp. 86-94
Open Access | Times Cited: 6
Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections.
Francine Ntoumi, Eskild Petersen, Peter Mwaba, et al.
International Journal of Infectious Diseases (2022) Vol. 124, pp. S69-S74
Open Access | Times Cited: 4
Inhibition of the Extracellular Signal–Regulated Kinase/Ribosomal S6 Kinase Cascade Limits Chlamydia trachomatis Infection
Yaohua Xue, Wentao Chen, Zhida Mai, et al.
Journal of Investigative Dermatology (2020) Vol. 141, Iss. 4, pp. 852-862.e6
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top